Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 7/2014

01-07-2014

Copy Number Variation in CCND1 Gene Is Implicated in the Pathogenesis of Sporadic Parathyroid Carcinoma

Authors: Lin Zhao, Li-hao Sun, Dong-mei Liu, Xiao-yan He, Bei Tao, Guang Ning, Jian-min Liu, Hong-yan Zhao

Published in: World Journal of Surgery | Issue 7/2014

Login to get access

Abstract

Background

The molecular bases for parathyroid carcinomas present in conjunction with sporadic primary hyperparathyroidism are not fully elucidated. Gene copy number variations (CNVs) play an important role in tumorigenesis. The aim of the current study was to explore whether the CNVs of specific tumor-associated genes are involved in parathyroid carcinogenesis.

Methods

A multiplex ligation-dependent probe amplification method was used to compare differences in copy number in 39 common tumor-associated genes among 7 patients with parathyroid carcinoma and 14 age- and sex-matched subjects with parathyroid adenoma.

Results

It was shown that amplification of CCND1, a gene encoding cyclin D1, was more prevalent in parathyroid carcinomas than in adenomas (71 vs. 21 %, p = 0.056). This result was confirmed quantitatively by real-time polymerase chain reaction. Expression of CCND1 mRNA level was significantly higher in carcinomas than in adenomas (p = 0.003). Western blot and immunohistochemical analysis also demonstrated higher expression of CCND1 in carcinoma specimens than in adenoma samples.

Conclusions

It is thus inferred that gain in copy number of CCND1 is implicated in the molecular pathogenesis of parathyroid carcinoma.
Literature
1.
2.
Obara T, Okamoto T, Kanbe M et al (1997) Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 13:134–141PubMedCrossRef
3.
Lee YS, Hong SW, Jeong JJ et al (2010) Parathyroid carcinoma: a 16-year experience in a single institution. Endocr J 57:493–497PubMedCrossRef
4.
Pradeep PV, Jayashree B, Mishra A et al (2011) Systematic review of primary hyperparathyroidism in India: the past, present, and the future trends. Int J Endocrinol 2011:921814PubMedCentralPubMedCrossRef
5.
Zhao L, Liu JM, He XY et al (2013) The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab 98:721–728PubMedCrossRef
6.
7.
Ricci G, Assenza M, Barreca M et al (2012) Parathyroid carcinoma: the importance of high clinical suspicion for a correct management. Int J Surg Oncol 2012:649148PubMedCentralPubMed
8.
Bricaire L, Odou MF, Cardot-Bauters C et al (2013) Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98:E403–E408PubMedCrossRef
9.
Lee C, Iafrate AJ, Brothman AR (2007) Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. Nat Genet 39:S48–S54PubMedCrossRef
10.
Rogers AJ, Chu JH, Darvishi K et al (2013) Copy number variation prevalence in known asthma genes and their impact on asthma susceptibility. Clin Exp Allergy 43:455–462PubMedCentralPubMedCrossRef
11.
12.
Wheeler E, Huang N, Bochukova EG et al (2013) Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45:513–517PubMedCentralPubMedCrossRef
13.
Agarwal SK, Schrock E, Kester MB et al (1998) Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 106:30–36PubMedCrossRef
14.
15.
Schouten JP, McElgunn CJ, Waaijer R et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 3:e57CrossRef
16.
Hogervorst FB, Nederlof PM, Gille JJ et al (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449–1453PubMed
17.
Eldering E, Spek CA, Aberson HL et al (2003) Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 31:e153PubMedCentralPubMedCrossRef
18.
Stuppia L, Antonucci I, Palka G et al (2012) Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci 13:3245–3276PubMedCentralPubMedCrossRef
19.
Moelans CB, Monsuur HN, de Pinth JH et al (2011) ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr) 34:489–494CrossRef
20.
Berge EO, Knappskog S, Geisler S et al (2010) Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer 9:173PubMedCentralPubMedCrossRef
21.
22.
Milne AN, Leguit R, Corver WE et al (2010) Loss of CDC4/FBXW7 in gastric carcinoma. Cell Oncol 32:347–359PubMed
23.
Hess CJ, Denkers F, Ossenkoppele GJ et al (2004) Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia 18:1981–1988PubMedCrossRef
24.
Veronese L, Tournilhac O, Combes P et al (2013) Contribution of MLPA to routine diagnostic testing of recurrent genomic aberrations in chronic lymphocytic leukemia. Cancer Genet 206:19–25PubMedCrossRef
25.
Jia H, Jiang X, Zhao Z et al (2009) High frequency of down-regulation of E-cadherin detected in benign sporadic insulinomas by multiplex ligation-dependent probe amplification. Hum Pathol 40:1336–1341PubMedCrossRef
26.
Newey PJ, Nesbit MA, Rimmer AJ et al (2012) Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab 97:E1995–E2005PubMedCrossRef
27.
Cromer MK, Starker LF, Choi M et al (2012) Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab 97:E1774–E1781PubMedCrossRef
28.
Bergero N, De Pompa R, Sacerdote C et al (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36:908–914PubMedCrossRef
29.
Haven CJ, Howell VM, Eilers PH et al (2004) Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64:7405–7411PubMedCrossRef
30.
Mohebati A, Shaha A, Shah J (2012) Parathyroid carcinoma: challenges in diagnosis and treatment. Hematol Oncol Clin North Am 26:1221–1238PubMedCrossRef
31.
Forsberg L, Bjorck E, Hashemi J et al (2005) Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology. Eur J Endocrinol 152:459–470PubMedCrossRef
32.
Woodard GE, Lin L, Zhang JH et al (2005) Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24:1272–1276PubMedCrossRef
33.
Imanishi Y, Hosokawa Y, Yoshimoto K et al (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093–1102PubMedCentralPubMedCrossRef
34.
Hsi ED, Zukerberg LR, Yang WI et al (1996) Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81:1736–1739PubMed
35.
Vasef MA, Brynes RK, Sturm M et al (1999) Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12:412–416PubMed
36.
Tahara H, Smith AP, Gas RD et al (1996) Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 56:599–605PubMed
37.
Friedman E, De Marco L, Gejman PV et al (1992) Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res 52:6804–6809PubMed
Metadata
Title
Copy Number Variation in CCND1 Gene Is Implicated in the Pathogenesis of Sporadic Parathyroid Carcinoma
Authors
Lin Zhao
Li-hao Sun
Dong-mei Liu
Xiao-yan He
Bei Tao
Guang Ning
Jian-min Liu
Hong-yan Zhao
Publication date
01-07-2014
Publisher
Springer US
Published in
World Journal of Surgery / Issue 7/2014
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2455-9

Other articles of this Issue 7/2014

World Journal of Surgery 7/2014 Go to the issue

OriginalPaper

Ethical Issues Regarding Related and Nonrelated Living Organ Donors

OriginalPaper

Is Adrenal Venous Sampling Mandatory before Surgical Decision in Case of Primary Hyperaldosteronism?

OriginalPaper

History and Evolution of Surgical Ethics: John Gregory to the Twenty-first Century

OriginalPaper

A Grounded Explanation of Why Women Present with Advanced Breast Cancer

OriginalPaper

Understanding the Burden and Outcome of Trauma Care Drives a New Trauma Systems Model

EditorialNotes

Surgical Ethics Symposium “Ethical Dilemmas in Surgical Practice”